ViGenCell Inc. (KOSDAQ:308080)
South Korea · Delayed Price · Currency is KRW 2,815.00
+10.00 (0.36%)
At close: Jun 27, 2025, 3:30 PM KST
ViGenCell Company Description
ViGenCell Inc. specializes in immune cell therapy.
It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use.
The company was founded in 1995 and is based in Seoul, South Korea.
ViGenCell Inc.
| Country | South Korea |
| Founded | 1995 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 64 |
| CEO | Kim Tai Gyu |
Contact Details
Address: Omnibus Park Building B(B-dong) Seoul, 06591 South Korea | |
| Phone | 82 2 2127 7590 |
| Website | vigencell.com |
Stock Details
| Ticker Symbol | 308080 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kim Tai Gyu | Chief Executive Officer |